primary glomerular diseases
Conditions
Interventions
Very low-dose group :None
Conventional-dose group:None
Sponsors
Department of Nephrology, Kidney Research Institute, West China Hospital of Sichuan University, Chengdu 610041, China
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: ?Patients hospitalized in the Department of Nephrology, West China Hospital, Sichuan University; ?Age: 15-80 years old; ?Diagnosed with primary glomerular disease, with a renal biopsy pathology report; ?Resistance to glucocorticoids and/or immunosuppressant therapy, Or repeated recurrence of the disease; ? treated with rituximab, and have at least 1 year of follow-up data in our hospital; ? monitored the absolute count of B cell subsets before and after treatment.
Exclusion criteria
Exclusion criteria: ?Patients who were treated with rituximab after initial diagnosis; ?Patients who were not followed up in our hospital.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proteinuria level; | — |
Secondary
| Measure | Time frame |
|---|---|
| CD 19 Count;Serum creatinine;Serum albumin level;Serum lipid level;Rituximab related adverse effect; | — |
Countries
China
Contacts
Public ContactPing Fu
West China School of Medicine and West China Hospital, Sichuan University
Outcome results
None listed